Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (331-340 of 442) with videos related to

Pageof 45
Sort By:
Clinical Genitourinary Cancer|August 4, 2014
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitorsDenis L F Jardim, Débora de Melo Gagliato, Gerald Falchook, et al.
Investigational New Drugs|September 25, 2021
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2009
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignanciesDavid S Hong, Said M Sebti, Robert A Newman, et al.
Oncotarget|April 21, 2017
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomasRoman Groisberg, David S Hong, Vijaykumar Holla, et al.
Journal for Immunotherapy of Cancer|September 20, 2019
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinomaMouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancersDavid S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
Immunotherapy|August 28, 2015
Strategies for combining immunotherapy with radiation for anticancer therapySteven N Seyedin, Jonathan E Schoenhals, Dean A Lee, et al.
Investigational New Drugs|February 20, 2025
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
European Journal of Endocrinology|March 25, 2022
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinomaSteven G Waguespack, Alexander Drilon, Jessica J Lin, et al.
Investigational New Drugs|November 3, 2021
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Pageof 45

Showing results (331-340 of 442) with videos related to

Sort By:
Pageof 45
Clinical Genitourinary Cancer|August 4, 2014
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitorsDenis L F Jardim, Débora de Melo Gagliato, Gerald Falchook, et al.
Investigational New Drugs|September 25, 2021
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2009
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignanciesDavid S Hong, Said M Sebti, Robert A Newman, et al.
Oncotarget|April 21, 2017
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomasRoman Groisberg, David S Hong, Vijaykumar Holla, et al.
Journal for Immunotherapy of Cancer|September 20, 2019
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinomaMouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancersDavid S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
Immunotherapy|August 28, 2015
Strategies for combining immunotherapy with radiation for anticancer therapySteven N Seyedin, Jonathan E Schoenhals, Dean A Lee, et al.
Investigational New Drugs|February 20, 2025
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
European Journal of Endocrinology|March 25, 2022
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinomaSteven G Waguespack, Alexander Drilon, Jessica J Lin, et al.
Investigational New Drugs|November 3, 2021
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Pageof 45